Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Gastrointestinal Stromal Tumors

ClinicalTrials.gov lists 335 trials for Gastrointestinal Stromal Tumors or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 25.

MeSH D046152 Neoplasms Neoplasm C04 C06 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 45 Phase 1/2 Phase 1/2 20 Phase 2 Phase 2 112 Phase 2/3 Phase 2/3 2 Phase 3 Phase 3 36 Phase 4 Phase 4 10 Not applicable Not applicable 32 Observational Observational 70 Phase 1 Phase 1 45 Phase 1/2 Phase 1/2 20 Phase 2 Phase 2 112 Phase 2/3 Phase 2/3 2 Phase 3 Phase 3 36 Phase 4 Phase 4 10 Not applicable Not applicable 32 Observational Observational 70

Trials per phase (log scale)

1 more section with rows

335 of the 335 trials are tagged with Gastrointestinal Stromal Tumors itself; the rest are tagged with a narrower condition beneath it.

Get the Gastrointestinal Stromal Tumors report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Gastrointestinal Stromal Tumors trials start? (29)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 24

1997: 2 trials (Observational 1, Phase 2 1) 1999: 2 trials (Phase 2 2) 2000: 10 trials (Phase 3 1, Phase 2 3, Phase 1/2 3, Phase 1 3) 2001: 5 trials (Phase 3 1, Phase 2 1, Phase 1/2 1, Phase 1 2) 2002: 9 trials (Observational 2, Phase 3 1, Phase 2 4, Phase 1/2 1, Phase 1 1) 2003: 4 trials (Not applicable 1, Phase 3 1, Phase 2 1, Phase 1 1) 2004: 8 trials (Not applicable 1, Phase 4 1, Phase 3 3, Phase 2 2, Phase 1 1) 2005: 13 trials (Observational 1, Phase 4 1, Phase 2 8, Phase 1/2 1, Phase 1 2) 2006: 7 trials (Observational 1, Phase 2 4, Phase 1 2) 2007: 13 trials (Observational 2, Not applicable 1, Phase 3 3, Phase 2 3, Phase 1/2 1, Phase 1 3) 2008: 24 trials (Observational 7, Not applicable 1, Phase 4 3, Phase 3 3, Phase 2 9, Phase 1 1) 2009: 11 trials (Observational 1, Not applicable 2, Phase 3 4, Phase 2 3, Phase 1 1) 2010: 8 trials (Observational 1, Phase 3 2, Phase 2 3, Phase 1/2 1, Phase 1 1) 2011: 17 trials (Observational 2, Not applicable 3, Phase 3 3, Phase 2 8, Phase 1 1) 2012: 11 trials (Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 6, Phase 1 2) 2013: 12 trials (Observational 5, Phase 4 2, Phase 2 3, Phase 1/2 1, Phase 1 1) 2014: 17 trials (Observational 8, Not applicable 1, Phase 3 1, Phase 2/3 1, Phase 2 4, Phase 1 2) 2015: 14 trials (Observational 3, Phase 3 1, Phase 2 4, Phase 1/2 2, Phase 1 4) 2016: 14 trials (Observational 2, Not applicable 4, Phase 4 1, Phase 3 1, Phase 2 3, Phase 1/2 2, Phase 1 1) 2017: 13 trials (Observational 1, Not applicable 1, Phase 2 9, Phase 1/2 1, Phase 1 1) 2018: 10 trials (Observational 1, Not applicable 1, Phase 3 3, Phase 2 3, Phase 1 2) 2019: 10 trials (Observational 2, Not applicable 2, Phase 3 1, Phase 2 2, Phase 1/2 2, Phase 1 1) 2020: 11 trials (Observational 4, Not applicable 2, Phase 3 1, Phase 2 2, Phase 1 2) 2021: 14 trials (Observational 4, Not applicable 2, Phase 4 1, Phase 2 2, Phase 1/2 1, Phase 1 4) 2022: 17 trials (Observational 8, Not applicable 2, Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 2) 2023: 10 trials (Observational 2, Not applicable 1, Phase 3 2, Phase 2 4, Phase 1/2 1) 2024: 10 trials (Observational 2, Not applicable 2, Phase 2 5, Phase 1/2 1) 2025: 15 trials (Observational 6, Not applicable 3, Phase 3 1, Phase 2 3, Phase 1 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 14
2025 15
2024 10
2023 10
2022 17
2021 14
2020 11
2019 10
2018 10
2017 13

Showing 10 of 29 earlier years.

Start your 14-day trial Email me all 29 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 17 trials starting in 2026 and about 16 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 33 trials still running at the 2026-10-09 snapshot; registered median of 38 months across 207 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Gastrointestinal Stromal Tumors trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 45
Phase 1/2 20
Phase 2 112
Phase 2/3 2
Phase 3 36
Phase 4 10
Not applicable 32
Observational 70
Expanded access 8

How many Gastrointestinal Stromal Tumors trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 8
Recruiting 46
Enrolling by invitation 1
Active, not recruiting 13
Available 2

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Gastrointestinal Stromal Tumors trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Novartis Pharmaceuticals 25
National Cancer Institute (NCI) 23
Deciphera Pharmaceuticals, LLC 9
Pfizer 9
European Organisation for Research and Treatment of Cancer - EORTC 7

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Gastrointestinal Stromal Tumors? (8)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Imatinib 60
Ripretinib 13
Avapritinib 6
Velzatinib 6
IPILIMUMAB 5

Showing 5 of 8 drugs.

Start your 14-day trial Email me all 8 drugs as a PDF

Interventions as named in the registry (7)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Sunitinib 4/2 26
Regorafenib Pill 16
Nilotinib Pill 13
Pazopanib Pill 3
D. Midazolam 3

Showing 5 of 7 interventions.

Start your 14-day trial Email me all 7 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Gastrointestinal Stromal Tumors trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Abdominal pain 234 33
Anaemia 166 20
Vomiting 148 33
Disease progression 146 14
Pyrexia 127 20

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Gastrointestinal Stromal Tumors? (337)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Head-to-Head Comparison of [<sup>68</sup>Ga]Ga-NOTA-RM26 and [<sup>18</sup>F]FDG PET/CT in Patients with Gastrointestinal Stromal Tumors: A Prospective Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2025 Yes
Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial. British journal of cancer 2025 Yes
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025 Yes
Personalized <i>N</i>-of-1 Combination Therapies for Advanced Gastrointestinal Stromal Tumors. JCO precision oncology 2025 Yes
Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research. Signal transduction and targeted therapy 2025 Yes

Showing 5 of 337 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (24)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Gastrointestinal stromal tumor Annual incidence 1-9 / 100 000 United States US Exact
Gastrointestinal stromal tumor Annual incidence 1-9 / 100 000 United States US Unspecified
Gastrointestinal stromal tumor Annual incidence 1-9 / 100 000 United States US Exact
Gastrointestinal stromal tumor Annual incidence 1-9 / 100 000 Hong Kong Not stated Exact
Gastrointestinal stromal tumor Annual incidence 1-9 / 100 000 Hong Kong Not stated Unspecified

Showing 5 of 24 prevalence observations.

Start your 14-day trial Email me all 24 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Gastrointestinal stromal tumor 44890 Exact Orphanet Rare Disease Ontology (ORDO)
Gastrointestinal stromal tumor 44890 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages